The First Peanut Allergy Therapy Might Soon Hit The Shelves, DBV Tech Reveals

DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff.

DBV Technologies, the first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate is Viaskin Peanut, a treatment to desensitize children from life-threatening peanut allergies for which DBV just released positive results in a Phase IIb clinical trial.

Back to news